SCYNEXIS (LTS:0L49) GF Score: 45/100 (As of Aug. 16, 2026) — 13% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L49 SCYNEXIS Inc LTS:0L49
45 GF Score
Price $5.27
GF Value $17.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SCYNEXIS GF Score?

SCYNEXIS LTS:0L49 +8.49% 45 GF Score is 45 as of Aug. 16, 2026, which is 13% above its 10-year median of 40.00. GuruFocus rates LTS:0L49 with a GF Score™ of 45/100 and a GF Value™ of $17.91 (Possible Value Trap). The stock has 3 warning signs investors should review.

SCYNEXIS has the GF Score of 45, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 3/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes SCYNEXIS might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

SCYNEXIS  (LTS:0L49) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

SCYNEXIS GF Score Related Terms

LTS:0L49 vs IXHL, ETST, INIS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's GF Score distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's GF Score falls into.


LTS:0L49
45GF Score
SCYNEXIS Inc LTS:0L49
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 45 mean?
SCYNEXIS (LTS:0L49) has a GF Score of 45 as of Aug. 16, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SCYNEXIS and its competitors. This is 13% above median its historical median of 40.00. Over the past decade, SCYNEXIS's GF Score has ranged from 2.00 to 61.00.
Is SCYNEXIS's GF Score too high?
SCYNEXIS's current GF Score of 45 is 13% above median its 10-year median of 40.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 61.00. Overall, SCYNEXIS has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's GF Score compare to IXHL and ETST?
SCYNEXIS's GF Score of 45 can be compared against companies in the Drug Manufacturers industry. Historically, SCYNEXIS's own GF Score has ranged from 2.00 to 61.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SCYNEXIS and its competitors. SCYNEXIS's current GF Score is 45, which is 13% above median its own 10-year median of 40.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (LTS:0L49) is currently considered Possible Value Trap. The stock's GF Value™ is $17.91, compared to a current price of $5.27 — trading 70.6% below its estimated fair value. The current GF Score is 45, which is 13% above median its 10-year median of 40.00. SCYNEXIS's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For SCYNEXIS (LTS:0L49), the current GF Score is 45 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SCYNEXIS (LTS:0L49) Overvalued in 2026?

Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued. The current stock price of $5.27 is trading 70.6% below its estimated GF Value™ of $17.91. GuruFocus considers SCYNEXIS to be Possible Value Trap.

Key valuation signals for LTS:0L49:

  • GF Score: 45 (13% above median its 10-year median of 40.00)
  • GF Value™: $17.91 vs. price of $5.27 (70.6% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the LTS:0L49 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SCYNEXIS Business Description

Other Exchanges SCYX:USA135:Germany
Address 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
45GF Score

Get the complete analysis for LTS:0L49

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price
$17.91
GF Value